Quia Pharma AB Company Description

Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform.

The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company’s Uni-Qleaver technology-platform.

The company was formerly known as QuiaPEG Pharmaceuticals Holding AB (publ) and changed its name to Quia Pharma AB (publ).

Quia Pharma AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.

Quia Pharma AB (publ)

Country	Sweden
Founded	2004
Industry	Biotechnology
Sector	Healthcare
Employees	3
CEO	Marcus Bosson

Contact Details

Address: Uppsala Business Park Uppsala, 754 50 Sweden
Phone	46 7 06 93 12 53
Website	quiapeg.com

Stock Details

Ticker Symbol	QUIA
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0001384850
SIC Code	2836

Key Executives

Name	Position
Marcus Bosson	MD, Chief Executive Officer and Director
Dr. Vidar Wendel-Hansen M.D., Ph.D.	Chief Medical Officer and Director
Hjordis Berg	Chief Financial Officer
Dr. Supaporn Sawadjoon	Head of Operations